Physician profile
Daniel J Sadowski
NPI 1376958637
$3,759.43
in general payments reported to CMS, 2019-2025
30 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $216 · 2021: $218 · 2022: $641 · 2023: $402 · 2024: $501 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.48 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $725.68 | 2019-2022 | |
| Astellas Pharma US INC | $433.56 | 2020-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $390.02 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $355.91 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, Lithovue |
| Procept Biorobotics Corporation | $193.16 | 2025 | |
| Dendreon Pharmaceuticals LLC | $192.99 | 2020-2025 | Provenge |
| Janssen Biotech, INC. | $184.02 | 2022-2024 | Erleada, Akeega, Balversa |
| Cook Medical LLC | $165.06 | 2019-2023 | Roadrunner |
| Bayer Healthcare Pharmaceuticals INC. | $158.87 | 2020-2022 | |
| Myovant Sciences INC. | $142.63 | 2022 | |
| Olympus America INC. | $103.47 | 2022-2025 | Itind System, Soltive |
| Abbvie INC. | $86.91 | 2021-2025 | |
| Endo USA, INC. | $67.68 | 2024-2025 | Xiaflex |
| Tempus Ai, INC | $66.86 | 2024-2025 | Xt Cdx |
| Endo Pharmaceuticals INC. | $65.25 | 2022-2023 | Xiaflex, Aveed |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $61.21 | 2022 | |
| Pfizer INC. | $54.94 | 2023-2025 | |
| Angiodynamics, INC. | $48.74 | 2022 | |
| Teleflex LLC | $38.21 | 2023-2025 | Barrigel, Urolift |
| Astrazeneca Pharmaceuticals LP | $34.31 | 2024 | Lynparza |
| Novartis Pharmaceuticals Corporation | $33.28 | 2025 | |
| Avyxa Pharma, LLC | $30.64 | 2025 | |
| Medtronic, INC. | $25.15 | 2023 | Interstim |
| Tolmar, INC. | $24.50 | 2023 | |
| Urogen Pharma, INC. | $22.12 | 2025 | |
| Cardinal Health 414 LLC | $13.47 | 2023 | |
| Neotract INC. | $12.47 | 2020 | |
| Convatec INC. | $11.43 | 2021 | |
| 180 Medical, INC. | $11.33 | 2020 | |
| Travere Therapeutics, INC. | $5.56 | 2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sadowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.